Ascend Capital’s Myriad Genetics MYGN Stock Holding History

Ascend Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-400,000	Closed	-$8.39M	–	216
2013 Q4	$8.39M	Buy	+400,000	New	+$10.1M	0.26%	107

Other funds holding MYGN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Ascend Capital's MYGN Position: Q1 2014 in Review

Ascend Capital sold out of Myriad Genetics (MYGN) in Q1 2014, closing a stake of 400,000 shares — an estimated $8.39M sold.

Ascend Capital first reported a position in MYGN in Q4 2013 and held it in 1 quarter. The position peaked at $8.39M in Q4 2013. 280 funds tracked by Wall St. Rank hold MYGN as of Q1 2014.

Ascend Capital reported no remaining Myriad Genetics position as of Q1 2014 after selling out during the quarter.
Ascend Capital sold 400,000 Myriad Genetics shares in Q1 2014, an estimated $8.39M.
Ascend Capital first reported a position in Myriad Genetics in Q4 2013 and held it in 1 quarter.
Ascend Capital's Myriad Genetics position peaked at $8.39M in Q4 2013.
280 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2014.

Based on Ascend Capital's 13F filing for Q1 2014, filed 14 May 2014.